1. Current and Emerging Treatments for IBD

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States.

4. IBD Background

5. Evolving Treatment Landscape in IBD

6. Limitations of Current IBD Therapies

7. Investigational Therapies: MOAs

8. Anti-Integrin Therapies

9. Selective Adhesion Molecule Inhibitors

10. Etrolizumab in Moderate to Severe UC Phase 2 Study

11. Etrolizumab in Moderate to Severe UC Phase 2 Study Results

12. Abrilumab in Moderate to Severe UC Phase 2b Study

13. Abrilumab in Moderate to Severe UC Phase 2b Study Results

14. PF-00547659 Anti-MAdCAM-1 Antibody TURANDOT Study

15. S1P Receptor Modulators

16. S1P Receptor Modulators (cont)

17. Ozanimod in Moderate to Severe UC TOUCHSTONE Study

18. TOUCHSTONE Efficacy Results

19. Emerging Anti-Interleukin mAbs in IBD

20. Ustekinumab for IBD

21. Risankizumab in Moderate to Severe CD Phase 2 Study

22. Risankizumab in Moderate to Severe CD Phase 2 Study Results

23. Brazikumab in Moderate to Severe CD Phase 2a Study

24. Mirikizumab in IBD

25. JAK Inhibitors

26. OCTAVE Trials: Tofacitinib in UC

27. OCTAVE 1 and 2 Efficacy Results

28. OCTAVE Sustain Efficacy Results

29. OCTAVE: Efficacy by Prior TNF Inhibitor Exposure

30. OCTAVE: Adverse Events

31. Filgotinib in Moderate to Severe CD FITZROY Study

32. Filgotinib in Moderate to Severe CD FITZROY Study Results

33. Upadacitinib in Moderate to Severe CD Celest Study

34. Upadacitinib in Moderate to Severe CD Celest Study Results

35. Other Emerging Therapies Rifaximin

36. Other Emerging Therapies in IBD

37. Possibilities for Future Treatment in IBD

38. Abbreviations

39. Abbreviations (cont)